Chemours Expects Double-Digit Opteon Growth and $5.7-$5.8B Sales in 2025, TSS Segment Outpaces Expectations

Friday, Nov 7, 2025 11:50 am ET1min read

Chemours expects double-digit growth for Opteon and $5.7B-$5.8B in sales for 2025, with the TSS segment outperforming expectations. Despite macroeconomic weakness affecting some sectors, the company exceeded adjusted EBITDA expectations due to diligent execution and operational improvements.

Chemours Expects Double-Digit Opteon Growth and $5.7-$5.8B Sales in 2025, TSS Segment Outpaces Expectations

Comments



Add a public comment...
No comments

No comments yet